AffyImmune Therapeutics

Matt Britz, President and Chief Operating Officer 

Oct. 10 | 5:00pm | Rentschler ATMP Ballroom 

Natick, MA 


AffyImmune is realizing the potential of cancer immunotherapy by extending the anti-cancer activity of CAR T cell therapy to solid tumors. AffyImmune’s proprietary technology allows fine-tuning of the affinity of CAR T cells to reduce toxicity and a tracking system to allow for real-time localization of CAR T cells after administration to patients. By affinity-tuning CAR T cells to select those targeting overexpressed but non-unique tumor associated antigens, we avoid toxicity to normal cells expressing lower levels of the target. Lower affinity CARs result in activation of CAR T cells in a manner more similar to the natural activation observed in non-engineered T cells. This more physiological activation leads to better serial tumor cell killing, clonal expansion, and long-term persistence to result in greater effectiveness. The company is approximately halfway through its Phase 1 trial of AIC100 to treat advanced thyroid cancers and is expanding to other cancers soon. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions